Timing isn't everything, but it sure helps. Six years ago, Warren Buffett, chairman of Berkshire Hathaway Inc.
Keep Reading →
December 9 - Hedge Funds - Comments
While John Paulson’s name is synonymous with outsized bets on mortgage-backed securities and gold, he also runs a fairly large equity portfolio at Paulson & Co, and it’s worth...
Keep Reading →
November 15 - Hedge Funds, News - Comments
Biotech bets. The first thing to know about Citadel and Ken Griffin is that they typically employ a high level of portfolio turnover on a quarterly basis.
Keep Reading →
November 15 - Hedge Funds, News - Comments
Clint Carlson of Carlson Capital has also shared his big bets from this fall.
Keep Reading →
November 14 - Hedge Funds, News - Comments
A growing number of managers of very large, well-known hedge fund firms have been going on a shopping spree, placing big bets on name-brand retailers or their suppliers in recent...
Keep Reading →
November 8 - Hedge Funds, News - Comments
Steven Cohen insider trading: It's no secret that Steven Cohen and SAC Capital are going through a rough patch, mainly because of the insider trading lawsuit initiated by the...
Keep Reading →
October 9 - Hedge Funds, News - Comments
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Keep Reading →
September 17 - News - Comments
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News - Comments
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News - Comments
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
September 4 - News - Comments
In the financial world, there are plenty of indicators shareholders can use to watch stocks. A couple of the best are hedge fund and insider trading activity.
Keep Reading →
September 3 - News - Comments
Today, let's look at investing giant Daniel Loeb, founder of the Third Point LLC hedge fund.
Keep Reading →
August 30 - Hedge Funds, News - Comments
Shares of Perrigo Company (NYSE:PRGO), one of the world's largest health care suppliers, slid with the broader market on Aug.
Keep Reading →
August 27 - News - Comments
Now, according to many of your fellow readers, hedge funds are seen as useless, old investment tools of a period lost to current times.
Keep Reading →
August 27 - News - Comments
To the average investor, there are a multitude of gauges shareholders can use to analyze their holdings. Two of the most useful are hedge fund and insider trading sentiment.
Keep Reading →
August 26 - News - Comments
Today let's look at investing giant Seth Klarman, who founded the Baupost Group hedge fund company back in 1982. Klarman is a successful investor with a lot to teach us.
Keep Reading →
August 23 - Hedge Funds - Comments
At the moment, there are tons of gauges investors can use to track Mr. Market. A duo of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
August 23 - News - Comments
Today, let's look at investing giant John Paulson. Founded in 1994 and owned by its employees, Paulson & Co.
Keep Reading →
August 21 - Hedge Funds - Comments
Several weeks after the end of each quarter, hedge funds and other major investors are required to file 13Fs with the SEC to disclose many of their long equity positions as of...
Keep Reading →
August 19 - Hedge Funds - Comments
Many market-watchers are scratching their heads about the pharmaceutical industry's latest blockbuster deal.
Keep Reading →
August 12 - News - Comments
Perrigo Company (NYSE:PRGO)’s acquisition of Elan Corporation, plc (ADR) (NYSE:ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying...
Keep Reading →
August 8 - News - Comments
Recently, Elan Corporation, plc (ADR) (NYSE:ELN) ended the fight against bids from Royalty Pharma.
Keep Reading →
August 7 - News - Comments
2013 is turning out to be a stellar year for Mergers and Acquisitions. There have been a number of M&A deals in healthcare and technology sectors.
Keep Reading →
August 6 - News - Comments
The chances are good that you're a bad investor.
Keep Reading →
August 5 - News - Comments
A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline.
Keep Reading →
August 5 - News - Comments
When I interviewed Alkermes Plc (NASDAQ:ALKS)' CEO Richard Pops last year, he described the relocation of the company's headquarters to Ireland where taxes are lower after buying...
Keep Reading →
July 30 - News - Comments
After months of fighting off the advances of unwanted suitor Royalty Pharma, Irish biotech Elan Corporation, plc (ADR) (NYSE:ELN) finally got an offer it couldn't refuse -- from...
Keep Reading →
July 29 - News - Comments
By now you've probably at least heard of SAC Capital, the massive hedge fund founded and run by the eponymous Steven A. Cohen.
Keep Reading →
July 29 - News - Comments
Editor's Note: Related tickers: Chipotle Mexican Grill, Inc. (NYSE:CMG), Herbalife Ltd. (NYSE:HLF), Hess Corp. (NYSE:HES), Citigroup Inc (NYSE:C), Goldman Sachs Group, Inc.
Keep Reading →
July 19 - Hedge Funds - Comments
Elan Corporation, plc (ADR) (NYSE:ELN)'s board unanimously rebuffed a $6.7 billion takeover offer from Royalty Pharma in early June and hired Citigroup Inc.
Keep Reading →
July 2 - News - Comments
According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion...
Keep Reading →
July 2 - News - Comments
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News - Comments
Eli Lilly & Co.
Keep Reading →
June 18 - News - Comments
Recently Elan Corporation, plc (ADR) (NYSE:ELN)'s shareholders voted against management's proposal to invest $1 billion in Theravance Inc (NASDAQ:THRX), a deal which a fellow...
Keep Reading →
June 18 - News - Comments
Elan Corporation, plc (ADR) (NYSE:ELN) has been in the news over the past few months because of a hotly contested battle with Royalty Pharma. The battle began on Feb.
Keep Reading →
June 18 - News - Comments
It's understandably very tempting for people with inside information to trade biotech stocks.
Keep Reading →
June 17 - News - Comments
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
June 17 - News - Comments
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
Keep Reading →
June 17 - News - Comments
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track Mr. Market.
Keep Reading →
May 30 - News - Comments
Seth Klarman's Baupost Group, led by the famed value investor and author of Margin of Safety, recently revealed its public equity portfolio in its quarterly filing with the SEC...
Keep Reading →
May 22 - Hedge Funds - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
May 20 - News - Comments
Editor's Note: Related Tickers: Goldman Sachs Group, Inc. (NYSE:GS), Citigroup Inc. (NYSE:C), J.C. Penney Company, Inc. (NYSE:JCP), Herbalife Ltd.
Keep Reading →
May 17 - Hedge Funds - Comments
Back towards the end of April 2013, Theravance Inc (NASDAQ:THRX) surprised everyone when it announced plans to split into two separate companies.
Keep Reading →
May 14 - News - Comments
Following in the footsteps of Abbott Laboratories (NYSE:ABT) spinning out its drug division into AbbVie Inc (NYSE:ABBV), and Pfizer spinning out its animal health division into...
Keep Reading →
April 26 - News - Comments
After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corporation, plc (ADR) (...
Keep Reading →
April 18 - News - Comments
Biogen Idec Inc.
Keep Reading →
April 17 - News - Comments
Editor's Note: Related tickers: UBS AG (USA) (NYSE:UBS), Morgan Stanley (NYSE:MS), Goldman Sachs Group, Inc. (NYSE:GS), Groupon Inc (NASDAQ:GRPN), J.C. Penney Company, Inc.
Keep Reading →
April 16 - Hedge Funds - Comments
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Keep Reading →
March 28 - News - Comments
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
Keep Reading →
March 25 - News - Comments
Elan Corporation, plc (ADR) (NYSE:ELN) was in 22 hedge funds' portfolio at the end of December.
Keep Reading →
March 25 - News - Comments